NCT03823118View on ClinicalTrials.gov

S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

June 28, 2020

Study Completion Date

April 17, 2021

Conditions
Small Cell Lung Cancer Recurrent
Interventions
DRUG

S1/Anlotinib

Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles； S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.

Trial Locations (3)

317000

Taizhou Hospital, Wenzhou Medical University, Taizhou

Unknown

Enze Hospital, Taizhou

Sanmen People's Hospital, Taizhou

All Listed Sponsors
lead

Taizhou Hospital

OTHER

NCT03823118 - S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer | Biotech Hunter | Biotech Hunter